Magnetic nanoparticles for use in the treatment of tumors

Patent metadata

Field	Value
Publication number	US-11547721-B2
Application number	US-201917051329-A
Country	US
Kind code	B2
Filing date	May 3, 2019
Priority date	May 7, 2018
Publication date	Jan 10, 2023
Grant date	Jan 10, 2023

Abstract

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

First claim

The invention claimed is:

1. A magnetic iron oxide nanoparticle having cubic shape, provided with a polymeric coating comprising carboxylic groups on its surface, said nanoparticle being further functionalized with a platinum-based chemotherapeutic agent and with a targeting agent comprising an scFv antibody fragment, wherein said chemotherapeutic agent and said targeting agent are both attached to different carboxylic groups of said polymeric coating, by means of amino-poly(ethylene glycol) linkers, said linkers being the same or different from each other, wherein and said linkers are covalently bound to said carboxylic groups of the coating.

2. The nanoparticle of claim 1 , wherein said targeting agent comprises a scFv antibody fragment comprising a histidine tag, and wherein said amino-poly(ethylene glycol) linker intended for binding said targeting agent is an amino-poly(ethylene glycol) derivative of a Ni 2+ complex with nitrilotriacetic acid that binds to said targeting agent by complexation of Ni 2+ with said histidine tag.

3. The nanoparticle of claim 1 , wherein said targeting agent comprises a scFv antibody fragment that specifically binds to Frα folate receptor.

4. The nanoparticle of claim 3 , wherein said antibody fragment is a scFvC4 fragment having amino acid sequence SEQ ID NO: 1.

5. The nanoparticle of claim 1 , wherein said platinum-based chemotherapeutic agent is an oxaliplatinum, and wherein said amino-poly(ethylene glycol) linker intended for binding said chemotherapeutic agent is bound to the oxaliplatinum molecule by a dicarboxylic group in the oxaliplatinum molecule.

6. A pharmaceutical composition comprising a plurality of nanoparticles of claim 1 .

7. A method of treating tumors in a patient, comprising administering the pharmaceutical composition of claim 6 to a patient in need thereof.

8. The method of claim 7 , wherein the pharmaceutical composition is administered as part of a combination therapy of hyperthermia and chemotherapy.

9. The method of claim 7 , wherein said tumour is a tumour selected from among ovarian tumour, colorectal tumour and lung tumour.

10. A process for the preparation of the nanoparticle of claim 1 , comprising:
a) activating said nanoparticle with an amphiphilic polymer to form a coating having carboxylic groups exposed on the nanoparticle's surface;
b) preparing a platinum-based chemotherapeutic agent derivative with a first amino-poly(ethylene glycol) linker;
c) functionalizing the nanoparticle following activation with said chemotherapeutic agent derivative;
d) functionalizing the nanoparticle coming from step c) with a second amino-poly(ethylene glycol) linker; and
e) preparing a derivative of said antibody fragment and binding thereof to said second amino-poly(ethylene glycol) linker.

Assignees

• Consiglio Nazionale Ricerche
• Fondazione Irccs Istituto Naz Dei Tumori
• Fondazione St Italiano Tecnologia
• Univ Santiago Compostela
• Univ Degli Studi Genova

Inventors

• Barthel Markus
• Cassani Marco
• Figini Mariangela
• Granja Juan
• Pellegrino Teresa
• Quarta Alessandra

Classifications

• A61K47/6929 Primary

  the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• A61K9/167

  with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073) · CPC title

• A61K47/52

  the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient · CPC title

• A61P35/00

  Antineoplastic agents · CPC title